Neĭshtadt E L, Gnilevskaia Z U, Aĭnbinder N M
Vopr Onkol. 1975;21(7):48-53.
Chromosome abberations in cells of 4 ovarian cancer patients have been studied prior to and during the treatment with ThioTEPA. ThioTEPA was injected intraperitoneally once a week in a dose of 40 mg. The amount of abberant cells prior to the therapy averaged 7.8%. 14 days following the treatment the amount of cells with chromosome abberations reached its peak (88.6%). By the 21st day of ThioTEPA treatment, when a total dose of the drug was 120 mg, the number of cells with abberations rapidly decreased, and by the 28-35th day of treatment there was a fall up to the initial values. ThioTEPA induced in tumor cells chiefly abberations of chromatoid type that evidenced the injury of cells in a phase G2 of the cellular cycle. A decrease in the number of chromosome abberations in tumor cells during the treatment with chemotherapeutic drugs is a morphological indication of the appearance of drug resistance.
对4例卵巢癌患者的细胞在使用噻替派治疗前和治疗期间的染色体畸变情况进行了研究。噻替派每周腹腔注射1次，剂量为40mg。治疗前畸变细胞数量平均为7.8%。治疗14天后，染色体畸变细胞数量达到峰值（88.6%）。到噻替派治疗第21天，药物总剂量为120mg时，畸变细胞数量迅速减少，到治疗第28 - 35天降至初始值。噻替派在肿瘤细胞中主要诱导染色质样类型的畸变，这证明细胞周期G2期的细胞受到了损伤。化疗药物治疗期间肿瘤细胞中染色体畸变数量的减少是出现耐药性的形态学指征。
